新生儿疑似细菌感染早期静脉转口服阿莫西林-克拉维酸与全程静脉抗生素的非劣效随机试验(RAIN)
这项在荷兰17家医院开展的多中心、随机、开放标签、非劣效试验纳入510名疑似细菌感染的新生儿,比较早期静脉转口服阿莫西林-克拉维酸与全程静脉抗生素的疗效与安全性。结果显示两组28天累积再感染率相似,非劣效性成立,且口服组住院时间显著缩短,不良事件无统计学差异。
要点
- 早期静脉转口服阿莫西林-克拉维酸在疑似细菌感染新生儿中非劣效于全程静脉抗生素。
核心结论
- 在疑似细菌感染新生儿中,早期静脉转口服阿莫西林-克拉维酸非劣效于全程静脉抗生素,且未增加不良事件发生率。
研究设计与样本
- 多中心、随机、开放标签、非劣效试验,在荷兰17家医院招募510名胎龄≥35周、日龄0-28天、体重≥2 kg的疑似细菌感染新生儿。
关键数值与推荐
- 非劣效界值为3%,即口服组再感染率高于静脉组不足3%时拒绝原假设。
- 主要结局在完成第35天随访的意向性治疗人群和符合方案人群中评估。
临床怎么用
- 对于胎龄≥35周、日龄0-28天、体重≥2 kg的疑似细菌感染新生儿,可考虑早期从静脉抗生素转换为口服阿莫西林-克拉维酸治疗7天。
- 该策略可能缩短住院时间,且不增加再感染风险或不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Switching from intravenous antibiotic therapy to oral antibiotic therapy among neonates is not yet practised in high-income settings due to uncertainties about exposure and safety. We aimed to assess the efficacy and safety of early intravenous-to-oral antibiotic switch therapy compared with a full course of intravenous antibiotics among neonates with probable bacterial infection. METHODS: In this multicentre, randomised, open-label, non-inferiority trial, patients were recruited at 17 hospitals in the Netherlands. Neonates (postmenstrual age ≥35 weeks, postnatal age 0-28 days, bodyweight ≥2 kg) in whom prolonged antibiotic treatment was indicated because of a probable bacterial infection, were randomly assigned (1:1) to switch to an oral suspension of amoxicillin 75 mg/kg plus clavulanic acid 18·75 mg/kg (in a 4:1 dosing ratio, given daily in three doses) or continue on intravenous antibiotics (according to the local protocol). Both groups were treated for 7 days. The primary outcome was cumulative bacterial reinfection rate 28 days after treatment completion. A margin of 3% was deemed to indicate non-inferiority, thus if the reinfection rate in the oral amoxicillin-clavulanic acid group was less than 3% higher than that in the intravenous antibiotic group the null hypothesis would be rejected. The primary outcome was assessed in the intention-to-treat population (ie, all patients who were randomly assigned and completed the final follow-up visit on day 35) and the per protocol population. Safety was analysed in all patients who received at least one administration of the allocated treatment and who completed at least one follow-up visit. Secondary outcomes included clinical deterioration and duration of hospitalisation. This trial was registered with ClinicalTrials.gov, NCT03247920, and EudraCT, 2016-004447-36. FINDINGS: Between Feb 8, 2018 and May 12, 2021, 510 neonates were randomly assigned (n=255 oral amoxicillin-clavulanic group; n=255 intravenous antibiotic group). After excluding those who withdrew consent (n=4), did not fulfil inclusion criteria (n=1), and lost to follow-up (n=1), 252 neonates in each group were included in the intention-to-treat population. The cumulative reinfection rate at day 28 was similar between groups (one [<1%] of 252 neonates in the amoxicillin-clavulanic acid group vs one [<1%] of 252 neonates in the intravenous antibiotics group; between-group difference 0 [95% CI -1·9 to 1·9]; pnon-inferiority<0·0001). No statistically significant differences were observed in reported adverse events (127 [50%] vs 113 [45%]; p=0·247). In the intention-to-treat population, median duration of hospitalisation was significantly shorter in the amoxicillin-clavulanic acid group than the intravenous antibiotics group (3·4 days [95% CI 3·0-4·1] vs 6·8 days [6·5-7·0]; p<0·0001). INTERPRETATION: An early intravenous-to-oral antibiotic switch with amoxicillin-clavulanic acid is non-inferior to a full course of intravenous antibiotics in neonates with probable bacterial infection and is not associated with an increased incidence of adverse events. FUNDING: The Netherlands Organization for Health Research and Development, Innovatiefonds Zorgverzekeraars, and the Sophia Foundation for Scientific Research.
引用
- Keij FM, Kornelisse RF, Hartwig NG, et al. Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial. Lancet Child Adolesc Health. 2022. PMID: 36088952. doi:10.1016/S2352-4642(22)00245-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。